Medicare Covered Indication
CMS covers autologous platelet-rich plasma (PRP) for Medicare services only when ALL of the following criteria are met:
ALL of the following
The service is performed on or after April 13, 2021.
Autologous PRP is used to treat a chronic, non-healing diabetic wound.
The PRP is prepared using a device whose FDA-cleared indications include management of exuding cutaneous wounds, such as diabetic ulcers.
Treatment is provided for a duration not exceeding 20 weeks.<= 20 weeks
Experimental and Non-Covered Uses
Coverage is limited to the Medicare indication above. Commercial-member autologous PRP and the uses identified below are experimental, investigational, unproven, or nationally non-covered as specified.
Apply the applicable exclusion or non-covered-use rule
For commercial members, autologous PRP is considered experimental, investigational, or unproven because the effectiveness of these approaches has not been established.
Commercial-member determination.
Nationally non-covered or investigational uses
Autologous PDGF for chronic, non-healing cutaneous wounds.
Becaplermin, a non-autologous growth factor, for chronic, non-healing subcutaneous wounds.
Autologous PRP for acute surgical wounds when applied directly to a closed incision, or for dehiscent wounds.
Any other form of autologous platelet-derived growth factor, including use for the conditions listed in this policy, is investigational and experimental.
Coverage criteria: Autologous platelet-derived growth factor (PDGF) is covered for chronic, non-healing cutaneous wounds. Becaplermin, a non-autologous growth factor, is covered for chronic, non-healing subcutaneous wounds.
Autologous PRP for acute surgical wounds is not covered when applied directly to a closed incision or when used for dehiscent wounds.
SummaCare does not cover other forms of autologous platelet-derived growth factors and considers them investigational and experimental for the following conditions and uses: chronic urticaria; alopecia areata (androgenetic alopecia); cervical radiculopathy; lateral epicondylitis; plantar fasciitis; temporomandibular joint (TMJ) dislocation; tendinopathies, including elbow, heel, knee, patella, and shoulder; Achilles tendon ruptures; anterior cruciate ligament surgery; use as adjunctive material to bone graft; avascular necrosis of the hip; cerebral palsy; Crohn's disease-related perianal fistula; gastrocnemius tear; hamstring tear; hip fractures; lumbar facet joint syndrome; osteoarthritis; rotator cuff injuries; urethral stricture; platelet gel application following total knee arthroplasty; platelet-rich plasma combined with stem cells (Regenexx); bone marrow-derived mesenchymal stromal cell administration for Crohn's disease and osteoarthritis; adipose-tissue-derived stem cell injection treatment for chondromalacia patellae; persistent epithelial defects of the cornea; sinus augmentation procedures; Dupuytren's contracture; tonsillectomy; ganglion cyst; osteonecrosis of the jaw; chronic, non-healing cutaneous wounds; becaplermin for chronic, non-healing subcutaneous wounds; and autologous PRP for acute surgical wounds when applied directly to a closed incision or for dehiscent wounds.
Contraindication: Platelet Dysfunction Syndrome.
Contraindication: Thrombocytopenia.
Contraindication: Malignancies or tumors located in the wound.
Contraindication: Hemodynamic instability.
Contraindication: Hyperfibrinogenemia.
For commercial members, SummaCare considers autologous PRP experimental, investigational, or unproven because the effectiveness of these approaches has not been established.
Autologous platelet-derived growth factor uses outside the CMS-covered indication for chronic, non-healing diabetic wounds are considered investigational. The CMS-covered indication requires treatment of a chronic, non-healing diabetic wound using autologous PRP prepared by a device with FDA-cleared indications that include management of exuding cutaneous wounds, such as diabetic ulcers, and is limited to 20 weeks for services performed on or after April 13, 2021.